1. Wenbo Z, Yan Z. The Uses of Anabolic Androgenic Steroids Among Athletes; Its Positive and Negative Aspects- A Literature Review. J Multidiscip Healthc. 2023 Dec 29;16:4293-4305. doi: 10.2147/JMDH.S439384.
2. Bulens A, Calzo JP, Eik-Nes TT, Beccia A, Raffoul A, Sarda V, Austin SB. Anabolic Steroid Initiation Among Boys and Young Men After Use of Muscle-Building Supplements. JAMA Netw Open. 2024 Dec 2;7(12):e2450566. doi: 10.1001/jamanetworkopen.2024.50566.
3. Oleksak P, Nepovimova E, Valko M, Alwasel S, Alomar S, Kuca K. Comprehensive analysis of prohibited substances and methods in sports: Unveiling trends, pharmacokinetics, and WADA evolution. Environ Toxicol Pharmacol. 2024 Jun;108:104447. doi: 10.1016/j.etap.2024.104447.
4. Alizadeh Pahlavani H, Veisi A. Possible consequences of the abuse of anabolic steroids on different organs of athletes. Arch Physiol Biochem. 2025 Feb 3:1-18. doi: 10.1080/13813455.2025.2459283.
5. Smoliga JM, Wilber ZT, Robinson BT. Premature Death in Bodybuilders: What Do We Know? Sports Med. 2023 May;53(5):933-948. doi: 10.1007/s40279-022-01801-0.
6. Windfeld-Mathiasen J, Heerfordt IM, Dalhoff KP, Trærup Andersen J, Andersen MA, Johansson KS, Biering-Sørensen T, Olsen FJ, Horwitz H. Cardiovascular Disease in Anabolic Androgenic Steroid Users. Circulation. 2025 Feb 13. doi: 10.1161/CIRCULATIONAHA.124.071117.
7. Windfeld-Mathiasen J, Heerfordt IM, Dalhoff KP, Andersen JT, Horwitz H. Mortality Among Users of Anabolic Steroids. JAMA. 2024 Apr 9;331(14):1229-1230. doi: 10.1001/jama.2024.3180.
8. Piatkowski T, De Andrade D, Neumann D, Tisdale C, Dunn M. Examining the association between trenbolone, psychological distress, and aggression among males who use anabolic-androgenic steroids. Int J Drug Policy. 2024 Dec;134:104636. doi: 10.1016/j.drugpo.2024.104636.
9. Piatkowski T, Whiteside B, Robertson J, Henning A, Lau EHY, Dunn M. What is the prevalence of anabolic-androgenic steroid use among women? A systematic review. Addiction. 2024 Dec;119(12):2088-2100. doi: 10.1111/add.16643.
10.Nolan T. Mortality of anabolic steroids users and other research. BMJ. 2024 Mar 21;384:q680. doi: 10.1136/bmj.q680.
11.Adami PE, Koutlianos N, Baggish A, Bermon S, Cavarretta E, Deligiannis A, Furlanello F, Kouidi E, Marques-Vidal P, Niebauer J, Pelliccia A, Sharma S, Solberg EE, Stuart M, Papadakis M. Cardiovascular effects of doping substances, commonly prescribed medications and ergogenic aids in relation to sports: a position statement of the sport cardiology and exercise nucleus of the European Association of Preventive Cardiology. Eur J Prev Cardiol. 2022 Mar 25;29(3):559-575. doi: 10.1093/eurjpc/zwab198.
12.Skoupá K, Šťastný K, Sládek Z. Anabolic Steroids in Fattening Food-Producing Animals-A Review. Animals (Basel). 2022 Aug 18;12(16):2115. doi: 10.3390/ani12162115.
13.Choi GJ, Kang H. Introduction to Umbrella Reviews as a Useful Evidence-Based Practice. J Lipid Atheroscler. 2023 Jan;12(1):3-11. doi: 10.12997/jla.2023.12.1.3.
14.Gates M, Gates A, Pieper D, Fernandes RM, Tricco AC, Moher D, Brennan SE, Li T, Pollock M, Lunny C, Sepúlveda D, McKenzie JE, Scott SD, Robinson KA, Matthias K, Bougioukas KI, Fusar-Poli P, Whiting P, Moss SJ, Hartling L. Reporting guideline for overviews of reviews of healthcare interventions: development of the PRIOR statement. BMJ. 2022 Aug 9;378:e070849. doi: 10.1136/bmj-2022-070849.
15.Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA; PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015 Jan 1;4(1):1. doi: 10.1186/2046-4053-4-1.
16.Campbell M, McKenzie JE, Sowden A, Katikireddi SV, Brennan SE, Ellis S, Hartmann-Boyce J, Ryan R, Shepperd S, Thomas J, Welch V, Thomson H. Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. BMJ. 2020 Jan 16;368:l6890. doi: 10.1136/bmj.l6890.
17.Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, Koffel JB; PRISMA-S Group. PRISMA-S: an extension to the PRISMA statement for reporting literature searches in systematic reviews. J Med Libr Assoc. 2021 Apr 1;109(2):174-200. doi: 10.5195/jmla.2021.962.
18.McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement. J Clin Epidemiol. 2016 Jul;75:40-6. doi: 10.1016/j.jclinepi.2016.01.021.
19.Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, Moher D, Tugwell P, Welch V, Kristjansson E, Henry DA. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017 Sep 21;358:j4008. doi: 10.1136/bmj.j4008.
20.Benzies KM, Premji S, Hayden KA, Serrett K. State-of-the-evidence reviews: advantages and challenges of including grey literature. Worldviews Evid Based Nurs. 2006;3(2):55-61. doi: 10.1111/j.1741-6787.2006.00051.x.
21.Amir-Behghadami M, Janati A. Population, Intervention, Comparison, Outcomes and Study (PICOS) design as a framework to formulate eligibility criteria in systematic reviews. Emerg Med J. 2020 Jun;37(6):387. doi: 10.1136/emermed-2020-209567.
22.McHugh ML. Interrater reliability: the kappa statistic. Biochem Med (Zagreb). 2012;22(3):276-82. PMID: 23092060.
23.Pieper D, Antoine SL, Mathes T, Neugebauer EA, Eikermann M. Systematic review finds overlapping reviews were not mentioned in every other overview. J Clin Epidemiol. 2014;67(4):368-375. doi:10.1016/j.jclinepi.2013.11.007.
24.Kirvalidze M, Abbadi A, Dahlberg L, Sacco LB, Calderón-Larrañaga A, Morin L. Estimating pairwise overlap in umbrella reviews: Considerations for using the corrected covered area (CCA) index methodology. Res Synth Methods. 2023 Sep;14(5):764-767.doi: 10.1002/jrsm.1658.